
Sign up to save your podcasts
Or


In this episode of Industry Focus: Financials, host Jason Moser sits down with Amalgamated Bank (NASDAQ: AMAL) CEO Keith Mestrich to talk about the opportunities and challenges of operating a smaller and socially-responsible bank in the modern financial landscape. Plus, Fool.com contributor Matt Frankel, CFP discusses what Wells Fargo (NYSE: WFC) CEO Tim Sloan’s abrupt departure could mean for the bank and its investors. And, you’ll hear which two stocks we’re watching this week.
Check out more of our content here:
Thanks to Grammarly for supporting The Motley Fool.
For 20% off a Grammarly premium account, go to http://www.Grammarly.com/Fool.
Another unicorn is going public! We take a look at Pinterest's prospectus and explain how the social media company has turned DIY pics into a $12B business.
Stocks: PINS, FB, GOOG, GOOGL
Check out more of our content here:
Another unicorn is going public! We take a look at Pinterest's prospectus and explain how the social media company has turned DIY pics into a $12B business.
Stocks: PINS, FB, GOOG, GOOGL
Check out more of our content here:
On March 8, 2018, the United States enacted 25% tariffs on imported steel. A year later, have those tariffs accomplished what they set out to do? Motley Fool Contributor Jason Hall and Industry Focus host Nick Sciple answer that question and share their favorite steel investment on this week’s episode.
On March 8, 2018, the United States enacted 25% tariffs on imported steel. A year later, have those tariffs accomplished what they set out to do? Motley Fool Contributor Jason Hall and Industry Focus host Nick Sciple answer that question and share their favorite steel investment on this week’s episode.
Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.
Check out more of our content here:
Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.
Check out more of our content here:
Amazon has increased its focus on profitability and that means getting rid of items where it “can’t realized a profit” or CRaP as the company unofficially calls them. Host Shannon Jones and Fool Contributor Daniel Kline also discuss whether CVS selling CBD products fits its image as a company focused on health.
Check out more of our content here:
Amazon has increased its focus on profitability and that means getting rid of items where it “can’t realized a profit” or CRaP as the company unofficially calls them. Host Shannon Jones and Fool Contributor Daniel Kline also discuss whether CVS selling CBD products fits its image as a company focused on health.
Check out more of our content here:
In the latest edition of our Between Two Fools interview series, host Jason Moser sits down with Ellevest CEO and co-founder Sallie Krawckeck. Then, Fool.com contributor Matt Frankel, CFP tells investors what they need to know about the latest Federal Reserve meeting and why bank stocks have been dropping ever since. Finally, you’ll hear which two stocks are on our watch lists this week.
Check out more of our content here:
From the publisher's feed

3,160 Listeners

807 Listeners

934 Listeners

1,604 Listeners